Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 41,900 shares, a decrease of 40.8% from the March 15th total of 70,800 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average daily trading volume, of 1,820,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC acquired a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Stock Up 2.6 %

NASDAQ CYCN traded up $0.07 during trading hours on Friday, reaching $2.75. 2,645 shares of the company were exchanged, compared to its average volume of 1,310,992. The stock has a market capitalization of $7.45 million, a P/E ratio of -2.25 and a beta of 1.96. Cyclerion Therapeutics has a 1 year low of $1.27 and a 1 year high of $9.47. The business’s 50 day simple moving average is $2.69 and its 200-day simple moving average is $2.86.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $1.81 million for the quarter.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.